Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalEDTXF 10 Days Payable is 2,569.72 as of Mar. 2026, which is 539% above its 10-year median of 402.35. GuruFocus rates EDTXF with a GF Score™ of 10/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Spectral Medical ranks better than 93.68% on this metric.
The historical rank and industry rank for Spectral Medical's Days Payable or its related term are showing as below:
EDTXF'
s Days Payable Range Over the Past 10 Years
Min: 139.54 Med: 402.35 Max: 942.12
Current: 836.25
During the past 13 years, Spectral Medical's highest Days Payable was 942.12. The lowest was 139.54. And the median was 402.35.
EDTXF's Days Payable is ranked better than 93.68% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs EDTXF: 836.25
Spectral Medical's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (2,569.72).
It may suggest that Spectral Medicaldelayed paying its suppliers.
Spectral Medical Days Payable Related Terms
Spectral Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Spectral Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Spectral Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (EDTXF) has a Days Payable of 2,569.72 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Spectral Medical and its competitors. This is 539% above median its historical median of 402.35. Over the past decade, Spectral Medical's Days Payable has ranged from 139.54 to 942.12. According to the industry distribution chart, Spectral Medical ranks #12 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 6.3%.
Is Spectral Medical's Days Payable too high?
Spectral Medical's current Days Payable of 2,569.72 is 539% above median its 10-year median of 402.35. Over the past 10 years, this metric has ranged from a low of 139.54 to a high of 942.12. The Medical Diagnostics & Research industry median Days Payable is 64.64. Spectral Medical's value of 2,569.72 is 3875.4% above this industry median. Based on the distribution chart, Spectral Medical ranks #12 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Spectral Medical has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #12 out of 190 companies for Days Payable. This places Spectral Medical in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.64. Spectral Medical's value of 2,569.72 is 3875.4% above this benchmark. Historically, Spectral Medical's own Days Payable has ranged from 139.54 to 942.12 over the past decade. While the company's 10-year median is 402.35 vs. the industry median of 64.64, Spectral Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current Days Payable of 2,569.72 is 3875.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Days Payable is 2,569.72, which is 539% above median its own 10-year median of 402.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (EDTXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.95 — trading 46.2% above its estimated fair value. The current Days Payable is 2,569.72, which is 539% above median its 10-year median of 402.35 and 3875.4% above the Medical Diagnostics & Research industry median of 64.64. Spectral Medical's overall GF Score™ is 10/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Spectral Medical (EDTXF), the current Days Payable is 2,569.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (EDTXF) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of $0.95 is trading 46.2% above its estimated GF Value™ of $0.65.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for EDTXF:
Days Payable: 2,569.72 (539% above median its 10-year median of 402.35)
GF Value™: $0.65 vs. price of $0.95 (46.2% above fair value)
Industry Position: 3875.4% above the Medical Diagnostics & Research median (#12 of 190)
No single metric tells the full story. See the EDTXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
10GF Score
Get the complete analysis for EDTXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDTXF has been successfully added to your 
